Amesite Third Quarter 2025 Earnings: US$0.16 loss per share (vs US$0.56 loss in 3Q 2024)
Net loss: US$663.4k (loss narrowed by 54% from 3Q 2024).
US$0.16 loss per share (improved from US$0.56 loss in 3Q 2024).
AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Amesite shares are up 37% from a week ago.
It is worth noting though that we have found 5 warning signs for Amesite that you need to take into consideration.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
High Throughput Process Development Strategic Business Report 2025-2030: Increasing Focus on Speed and Efficiency in Drug Discovery Expands Market Opportunities
The global High Throughput Process Development (HTPD) market, pivotal for the biopharmaceutical industry, is projected to grow from $15.3 billion in 2024 to $24.6 billion by 2030, at a CAGR of 8.3%. Key drivers include technological innovations in automation and data analytics. The market is segmented by product types, including consumables and software, with major growth forecasted in regions such as China and the U.S. The report offers insights into market trends, regional analysis, and profiles leading companies like Agilent Technologies and Danaher Corporation. High Throughput Process Development Market Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "High Throughput Process Development - Global Strategic Business Report" report has been added to global market for High Throughput Process Development was valued at US$15.3 Billion in 2024 and is projected to reach US$24.6 Billion by 2030, growing at a CAGR of 8.3% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the High Throughput Process Development market. The growth in the high throughput process development market is driven by several factors, including the increasing complexity of biologic drugs, the rising demand for personalized medicines, and advancements in automation and data analytics. As the biopharmaceutical industry shifts toward more complex therapeutics, such as gene and cell therapies, the need for efficient process optimization is more critical than ever. HTPD allows companies to streamline the development of these therapies, reducing both time and costs. The growing demand for biosimilars, which require rapid process development to compete with branded biologics, is also contributing to market growth. Additionally, the adoption of automation and machine learning in process development is further enhancing the efficiency and accuracy of bioprocess optimization, driving the market's throughput process development (HTPD) is a critical tool in the biopharmaceutical industry, enabling faster, more efficient development of biologic drugs. HTPD involves the use of automated, miniaturized experiments that allow researchers to test multiple process conditions simultaneously, significantly accelerating the optimization of production processes for therapeutic proteins, vaccines, and monoclonal antibodies. The ability to screen numerous variables at once reduces the time and resources needed to scale up bioprocesses, from lab-scale to commercial manufacturing. As biopharmaceutical companies face increasing pressure to reduce costs and bring therapies to market faster, HTPD has become indispensable in ensuring both process efficiency and product Are Technological Innovations Shaping High Throughput Process Development?Technological innovations, particularly in automation, robotics, and data analytics, have revolutionized high throughput process development. Automation systems now allow for the simultaneous running of hundreds of experiments, enabling researchers to optimize cell culture conditions, purification processes, and formulation strategies more efficiently. The integration of advanced data analytics and machine learning into HTPD platforms has further enhanced process optimization, allowing for predictive modeling and real-time decision-making. Microfluidic technologies, which allow for the precise control of small volumes of liquids, are also playing a critical role in reducing reagent use and increasing the speed of bioprocess optimization. These technologies are enabling biopharmaceutical companies to streamline their development timelines and reduce production Do Market Segments Define the Growth of the High Throughput Process Development Market?Product types include consumables, software, and instruments, with consumables like reagents and microplates holding the largest market share due to their constant need in HTPD workflows. Services such as contract research and process development outsourcing are also expanding, as biopharmaceutical companies increasingly seek external expertise to accelerate drug development. The biopharmaceutical industry, particularly companies focused on biologics such as monoclonal antibodies, is the primary end-user of HTPD, as it enables rapid scale-up from R&D to manufacturing. Other key users include academic and research institutes involved in biotechnology Scope Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as Agilent Technologies, Aurora Biomed, Axxam S.P.A., Bio-Rad Laboratories, Danaher Corporation and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Key Insights: Market Growth: Understand the significant growth trajectory of the Monoclonal Antibodies segment, which is expected to reach US$17.8 Billion by 2030 with a CAGR of a 9.1%. The Other Molecule Types segment is also set to grow at 6.5% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $3.9 Billion in 2024, and China, forecasted to grow at an impressive 12.6% CAGR to reach $6.4 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Segments Molecule Type (Monoclonal Antibodies, Other Molecule Types) Component (Tools & Systems, Consumables, Software, Other Components) Technology (Chromatography, Ultraviolet-Visible Spectroscopy, Other Technologies) End-Use (Biopharmaceutical Companies, Contract Research Organizations, Academic Research Institutes) Tariff Impact Analysis: Key Insights for 2025What's Included in This Edition: Tariff-adjusted market forecasts by region and segment Analysis of cost and supply chain implications by sourcing and trade exposure Strategic insights into geographic shifts Buyers receive a free July 2025 update with: Finalized tariff impacts and new trade agreement effects Updated projections reflecting global sourcing and cost shifts Expanded country-specific coverage across the industry Key Attributes: Report Attribute Details No. of Pages 89 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $15.3 Billion Forecasted Market Value (USD) by 2030 $24.6 Billion Compound Annual Growth Rate 8.3% Regions Covered Global Key Topics Covered: MARKET OVERVIEW Influencer Market Insights Tariff Impact on Global Supply Chain Patterns Global Economic Update High Throughput Process Development - Global Key Competitors Percentage Market Share in 2024 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E) MARKET TRENDS & DRIVERS Rising Demand for Biopharmaceuticals Drives Growth in High Throughput Process Development Technological Advancements in Automation and Robotics Propel Innovation in High Throughput Process Development Increasing Focus on Speed and Efficiency in Drug Discovery Expands Addressable Market for High Throughput Solutions Growing Adoption of High Throughput Technologies in Vaccine Development Spurs Market Growth Surge in Demand for Personalized Medicine Strengthens Business Case for High Throughput Process Development Increasing Use of High Throughput Screening in Protein and Antibody Discovery Expands Market Potential Technological Innovations in Microfluidics and Lab Automation Propel Market Innovation Growing Focus on Reducing Time-to-Market for Pharmaceuticals Drives Adoption of High Throughput Processes Rising Use of Artificial Intelligence (AI) in High Throughput Data Analysis Strengthens Competitive Advantage Increasing Focus on Process Optimization and Scalability in Biopharmaceutical Production Drives Innovation Rising Demand for High Throughput Analytical Techniques in Quality Control Expands Market Opportunities FOCUS ON SELECT PLAYERS:Some of the 33 companies featured in this report Agilent Technologies Aurora Biomed Axxam S.P.A. Bio-Rad Laboratories Danaher Corporation Eppendorf GE Healthcare Hamilton Company Merck Millipore Perkinelmer Sartorius Stedim Biotech Tecan Group Thermo Fisher Scientific, Inc. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment High Throughput Process Development Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
31 minutes ago
- Yahoo
Stock market today: S&P 500, Dow, Nasdaq futures stall with US and China set to reboot trade talks
US stock futures trod water on Monday ahead of renewed US-China trade talks in London, as investors watched for signs either side is willing to dial down tensions and reach a tariff deal. S&P 500 futures (ES=F) were little changed after the broad benchmark edged above 6,000 to notch its highest close since February. Dow Jones Industrial Average futures (YM=F) also fluctuated along the flat line, while contracts on the tech-heavy Nasdaq 100 (NQ=F) nudged 0.1% lower. Stocks ended last week on a high note, appearing to shake off the volatility that has plagued markets following President Trump's early-April tariff hikes. Encouraging jobs data helped ease fears of a recession fueled by his policy overhaul. Hopes are now for a breakthrough in the high-level US-China trade talks kicking off on Monday, after a phone call between Trump and Chinese President Xi last week. Read more: The latest on Trump's tariffs The stakes are high amid warnings that tariff barriers will harm economies worldwide — the US in particular. Investors are looking for a revival of the momentum shown in the Geneva pact in mid-May. Relations have soured since then, with the US and China accusing each other of not keeping to the trade truce and ratcheting up pressures in other areas. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
35 minutes ago
- Yahoo
Pharmaceutical Hot Melt Extrusion Equipment Report 2025: Market to Reach $44.8 Million by 2030 - Increasing Adoption of HME in Drug Solubility and Bioavailability Enhancement Expands Opportunities
The global Pharmaceutical Hot Melt Extrusion Equipment market is anticipated to grow from USD 34.7 Million in 2024 to USD 44.8 Million by 2030, at a CAGR of 4.3%. This growth is driven by the increasing demand for advanced drug manufacturing technology, enhancing drug solubility and bioavailability. Key highlights include the rise in Twin Screw Extruders, expected to reach $28 Million by 2030, and notable regional growth in China at a 6.5% CAGR. Major players include Baker Perkins, Coperion, and Thermo Fisher. Pharmaceutical Hot Melt Extrusion Equipment Market Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "Pharmaceutical Hot Melt Extrusion Equipment - Global Strategic Business Report" report has been added to global market for Pharmaceutical Hot Melt Extrusion Equipment was valued at US$34.7 Million in 2024 and is projected to reach US$44.8 Million by 2030, growing at a CAGR of 4.3% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Pharmaceutical Hot Melt Extrusion Equipment pharmaceutical industry is increasingly adopting HME technology as it enables the production of a wide range of dosage forms, including tablets, granules, films, and transdermal patches, without the need for solvents or complex downstream processing steps. The continuous nature of the HME process also supports the development of more efficient and scalable manufacturing operations, reducing production time and costs. The growth in the global pharmaceutical hot melt extrusion (HME) equipment market is driven by several factors, including the increasing demand for novel drug formulations, the rise in the number of poorly soluble drug candidates, and the ongoing advancements in pharmaceutical manufacturing technologies. One of the primary growth drivers is the growing need for solubility enhancement solutions to address the formulation challenges associated with poorly soluble APIs. As a significant proportion of new drug candidates discovered through modern drug development processes exhibit low solubility and bioavailability, pharmaceutical companies are seeking advanced formulation techniques such as HME to improve drug performance and therapeutic outcomes. HME's ability to produce amorphous solid dispersions and enhance the solubility of APIs is making it a critical tool in drug formulation, driving the demand for HME rise in the number of complex and targeted drug therapies, such as combination therapies and personalized medicine, is another key factor contributing to market growth. The development of these therapies requires advanced drug delivery systems that can achieve specific release profiles and deliver multiple APIs within a single dosage form. HME technology provides the flexibility and precision needed to create complex drug formulations with tailored release characteristics, supporting the development of innovative therapies that address unmet medical needs. The growing focus on personalized medicine, which involves tailoring treatments based on individual patient profiles, is driving the demand for HME equipment that can produce customized drug products with high precision and advancements in pharmaceutical manufacturing technologies are further supporting the growth of the HME equipment market. The adoption of continuous manufacturing, which integrates multiple processes into a single, streamlined production line, is gaining momentum in the pharmaceutical industry. HME equipment, with its continuous nature and ability to perform multiple processes within a single system, is a key enabler of continuous manufacturing. The use of HME in continuous production lines reduces production time, minimizes waste, and improves product quality, making it an attractive option for pharmaceutical manufacturers looking to enhance their operational efficiency. The integration of advanced control systems and automation technologies in HME equipment is further improving process control and product consistency, supporting the growth of the the increasing adoption of HME technology in the production of solid dispersions and controlled-release formulations is expanding the application scope of HME equipment. Solid dispersions are widely used to improve the dissolution rate and bioavailability of poorly soluble drugs, while controlled-release formulations provide sustained drug release over extended periods. HME's ability to produce these formulations with high precision and efficiency is driving its adoption in a wide range of therapeutic areas, including oncology, neurology, and pain management. The use of HME in developing abuse-deterrent formulations for controlled substances is also gaining traction, as it helps mitigate the risk of misuse and abuse of prescription the growing investment in pharmaceutical research and development (R&D) and the expansion of drug development pipelines are creating new opportunities for the HME equipment market. Pharmaceutical companies are investing in R&D to discover and develop new therapies for chronic and complex diseases, leading to an increase in the number of drug candidates that require advanced formulation techniques. The growing number of R&D projects focused on solubility enhancement, controlled-release formulations, and combination therapies is driving demand for HME equipment that supports these initiatives. The expansion of R&D activities in emerging markets such as Asia-Pacific and Latin America is further boosting demand for HME equipment, as these regions become hubs for pharmaceutical innovation and the impact of the COVID-19 pandemic has highlighted the importance of advanced manufacturing technologies in ensuring the availability and supply of essential medicines. The increased focus on developing novel therapies and vaccines during the pandemic has underscored the need for efficient and scalable manufacturing solutions. The adoption of HME technology, with its ability to produce complex formulations and support continuous manufacturing, is playing a critical role in meeting the growing demand for innovative drug products. As these factors converge, the global pharmaceutical hot melt extrusion equipment market is poised for robust growth, driven by technological advancements, expanding pharmaceutical development activities, and the increasing emphasis on developing innovative and patient-centric drug formulations across various therapeutic ScopeReport Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as Baker Perkins Ltd., Coperion GmbH, Leistritz AG, Milacron Holdings Corp., Thermo Fisher Scientific, Inc. and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Key Insights: Market Growth: Understand the significant growth trajectory of the Twin Screw Extruders segment, which is expected to reach US$28.0 Million by 2030 with a CAGR of a 4.1%. The Single Screw Extruder segment is also set to grow at 4.6% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $9.1 Million in 2024, and China, forecasted to grow at an impressive 6.5% CAGR to reach $9.5 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Segments End-Use (Research Laboratory, CMO, Pharma Companies) Product (Twin Screw Extruders, Single Screw Extruder, Laboratory Extruder, RAM Extruder) Tariff Impact Analysis: Key Insights for 2025What's Included in This Edition: Tariff-adjusted market forecasts by region and segment Analysis of cost and supply chain implications by sourcing and trade exposure Strategic insights into geographic shifts Buyers receive a free July 2025 update with: Finalized tariff impacts and new trade agreement effects Updated projections reflecting global sourcing and cost shifts Expanded country-specific coverage across the industry Key Attributes: Report Attribute Details No. of Pages 193 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $34.7 Million Forecasted Market Value (USD) by 2030 $44.8 Million Compound Annual Growth Rate 4.3% Regions Covered Global Key Topics Covered: MARKET OVERVIEW Influencer Market Insights Tariff Impact on Global Supply Chain Patterns Pharmaceutical Hot Melt Extrusion Equipment - Global Key Competitors Percentage Market Share in 2024 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E) MARKET TRENDS & DRIVERS Rising Demand for Solid Oral Dosage Forms Propels Growth in Pharmaceutical Hot Melt Extrusion Equipment Market Increasing Adoption of Hot Melt Extrusion (HME) in Drug Solubility and Bioavailability Enhancement Expands Addressable Market Technological Innovations in Twin-Screw and Continuous Extruders Strengthen Business Case for Market Growth Case Overview: Growth in Use of Hot Melt Extrusion in Sustained and Controlled Release Formulations Bodes Well for Market Expansion Rising Focus on Reducing Drug Development Time and Costs Drives Demand for HME Equipment Case Overview: Growth in Adoption of HME in Pediatric and Geriatric Drug Formulations Expands Market Reach Case Overview: Growth in Adoption of HME in Veterinary and Animal Health Products Expands Market Reach FOCUS ON SELECT PLAYERS:Some of the 44 companies featured in this report Baker Perkins Ltd. Coperion GmbH Leistritz AG Milacron Holdings Corp. Thermo Fisher Scientific, Inc. Xtrutech Ltd. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Pharmaceutical Hot Melt Extrusion Equipment Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
